COMPOSITION FOR SKIN SOOTHING CONTAINING LIQUID-PHASE PLASMA

    公开(公告)号:US20200261325A1

    公开(公告)日:2020-08-20

    申请号:US16648087

    申请日:2018-09-17

    Inventor: Chul Ho KIM

    Abstract: The present invention is to provide a composition for skin soothing, which is safe from a risk of side effects, and relates to a composition for skin soothing containing a liquid-phase plasma. The liquid-phase plasma of the present invention is obtained by applying plasma as pure energy to a liquid-phase material, and can be used in the skin sensitive to a chemical material without a risk of side effects. Furthermore, the liquid-phase plasma has remarkable effects on the prevention or treatment of dermatitis or photo-aging due to ultraviolet light, and thus is expected to be greatly used in beauty care and mechanical fields.

    Heterodimeric Fc-fused cytokine and pharmaceutical composition comprising the same

    公开(公告)号:US10696722B2

    公开(公告)日:2020-06-30

    申请号:US16323839

    申请日:2017-08-10

    Abstract: The present invention relates to a heterodimeric Fc-fused protein comprising a first Fc region and a second Fc region of an immunoglobulin Fc pair and a physiologically active protein composed of two or more different subunits, wherein one or more subunits of the physiologically active protein are linked separately to one or more ends of the N-terminus or C-terminus of the first Fc region and/or the second Fc region, and CH3 domains of the first Fc region and the second Fc region are mutated so as to promote the heterodimeric Fc formation. Moreover, the present invention relates to a pharmaceutical composition comprising the heterodimeric Fc-fused protein. The heterodimeric Fc-fused protein according to the present invention has an advantage in that it can retain the activity of a naturally occurring physiologically active protein whose two or more different subunits exhibit physiological activity by forming a protein complex, because the physiologically active protein can be linked to an immunoglobulin heterodimeric Fc such that the naturally occurring form and structure of the fused protein thereof can be maintained. When the heterodimeric Fc-fused protein according to the present invention is used, there is an advantage in that the in vivo half-life of the physiologically active protein contained in the heterodimeric Fc-fused protein can be significantly increased due to the Fc-mediated long half-life such that various physiological activities thereof in vivo can be long-lasting.

    APPARATUS AND METHOD FOR IDENTIFYING CLOSE CUT-IN VEHICLE AND VEHICLE INCLUDING APPARATUS

    公开(公告)号:US20200118441A1

    公开(公告)日:2020-04-16

    申请号:US16215113

    申请日:2018-12-10

    Abstract: A close cut-in vehicle identification apparatus includes an information generator configured to generate sensor fusion information, estimated vehicle state information, and risk determination information based on surrounding vehicle information upon receiving the surrounding vehicle information, a feature combination generator configured to extract a plurality of features based on the sensor fusion information, the estimated vehicle state information, and the risk determination information and to combine the extracted features to generate a plurality of feature combinations, a classification learner configured to classify and learn the plurality of feature combinations depending on a weight factor, and a vehicle intention determination device configured to determine intention of a surrounding vehicle based on a classification learning result value to select an optimum feature combination corresponding to identification of the close cut-in vehicle and configured to determine a situation of the close cut-in vehicle based on the selected optimum feature combination.

    Neuropilin-1 specific binding peptide, fusion protein fused with same, and use thereof

    公开(公告)号:US10400022B2

    公开(公告)日:2019-09-03

    申请号:US15560232

    申请日:2016-03-23

    Abstract: A peptide that binds specifically to neuropilin-1 (NRP1) without binding to neuropilin-2 (NRP2) is provided. A fusion protein, a fusion antibody, small-molecule drug, a nanoparticle, or a liposome, which comprises the peptide, and a pharmaceutical composition for treating or preventing cancer or angiogenesis-related diseases, and a composition for diagnosing cancer or angiogenesis-related diseases are provided. A polynucleotide encoding the peptide that binds specifically to NRP1 and a method for screening the peptide that binds specifically to NRP1 are provided. An antibody heavy-chain constant region Fc-fused peptide binding specifically to NRP1 has the property of binding specifically to NRP1, and thus when it is administered in vivo, it accumulates selectively in tumor tissue, and widens the intercellular space between tumor-associated endothelial cells to promote its extravasation and increases its tumor tissue penetration.

    Method and system of monitoring network

    公开(公告)号:US10397254B2

    公开(公告)日:2019-08-27

    申请号:US15145870

    申请日:2016-05-04

    Abstract: Provided are a method of monitoring a network driving apparatus provided in a network and a system thereof.The present invention provides a network monitoring method that performs monitoring which does not hinder existing network availability through a means for detouring a path of a packet transferred to a monitoring target apparatus by using one or more servers and clients connected to a network and further, provides extensibility which can be applied to the network using various communication protocols through a protocol converting means that detours the path of the packet after converting the existing protocol into a TCP/IP protocol.

Patent Agency Ranking